1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > AIM Therapeutics Inc. - Product Pipeline Review - 2013

AIM Therapeutics Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

AIM Therapeutics Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “AIM Therapeutics Inc. - Product Pipeline Review - 2013” provides data on the AIM Therapeutics Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, AIM Therapeutics Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from AIM Therapeutics Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- AIM Therapeutics Inc. - Brief AIM Therapeutics Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AIM Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of AIM Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the AIM Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate AIM Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of AIM Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AIM Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with AIM Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of AIM Therapeutics Inc. and identify potential opportunities in those areas.

Table Of Contents

AIM Therapeutics Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
AIM Therapeutics Inc. Snapshot 4
AIM Therapeutics Inc. Overview 4
Key Information 4
Key Facts 4
AIM Therapeutics Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
AIM Therapeutics Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
AIM Therapeutics Inc. - Pipeline Products Glance 9
AIM Therapeutics Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
AIM Therapeutics Inc. - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
AIM Therapeutics Inc. - Drug Profiles 11
200-Series Discovery Compounds 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
AIM-101 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
AIM-102 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
AIM-501 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
AIM Therapeutics Inc. - Pipeline Analysis 15
AIM Therapeutics Inc. - Pipeline Products by Therapeutic Class 15
AIM Therapeutics Inc. - Pipeline Products by Route of Administration 17
AIM Therapeutics Inc. - Recent Pipeline Updates 18
AIM Therapeutics Inc. - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables


AIM Therapeutics Inc., Key Information 4
AIM Therapeutics Inc., Key Facts 4
AIM Therapeutics Inc. - Pipeline by Indication, 2013 6
AIM Therapeutics Inc. - Pipeline by Stage of Development, 2013 7
AIM Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 8
AIM Therapeutics Inc. - Phase II, 2013 9
AIM Therapeutics Inc. - Pre-Clinical, 2013 10
AIM Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 16
AIM Therapeutics Inc. - Pipeline By Route of Administration, 2013 17
AIM Therapeutics Inc. - Recent Pipeline Updates, 2013 18

List of Figures


AIM Therapeutics Inc. - Pipeline by Indication, 2013 6
AIM Therapeutics Inc. - Pipeline by Stage of Development, 2013 7
AIM Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 8
AIM Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 15
AIM Therapeutics Inc. - Pipeline By Route of Administration, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.